source; lin
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sirona Biochem (SBM) has signed an agreement with WuXi AppTec to produce TFC-1326, a powerful active against the aging effects on skin
  • Sirona is in advanced discussions with a leading clinical trial provider to design the planned clinical trial
  • WuXi AppTec provides a broad portfolio of R&D and manufacturing services
  • Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology
  • Sirona Biochem Corp. (SBM) opened trading at C$0.31

Sirona Biochem (SBM) has signed an agreement with WuXi AppTec to produce TFC-1326, a powerful active against the aging effects on skin.

Years of groundbreaking research by Sirona has shown in preclinical studies that TFC-1326 has the potential to reverse the effects of aging on skin, including the potential to eliminate fine wrinkles. The company is now preparing for a clinical trial. 

The anti-aging and anti-wrinkle markets are estimated to be US$271 billion globally by 2024.

Sirona is in advanced discussions with a leading clinical trial provider to design the planned clinical trial. 

Dr. Howard Verrico, CEO of Sirona Biochem, commented on the potential of TFC-1326.

“There are many anti-aging and anti-wrinkle products available on the market currently. But to truly reverse the damage to the skin integrity that occurs naturally with aging is an area of unmet need. Our goal is to demonstrate clinically the potential of TFC-1326 to restore the integrity of the skin and return a more youthful appearance. The treatment of fine wrinkles is also a goal. BOTOX is the most effective on dynamic wrinkles while static wrinkles typically are managed by fillers. TFC-1326 has the potential to replace or supplement dermal filler injections to treat these static wrinkles. TFC-1326 with its unique mechanism of action is revolutionary in the aesthetic skin care space. We see this as an opportunity to showcase the tremendous potential of our platform technology. And, of course, we are pursuing another lucrative licensing agreement for TFC-1326.”

WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver ground-breaking treatments to patients.

Sirona Biochem Corp is a development stage biotechnology company whose principal activities include the development of cosmetic and pharmaceutical active ingredients.

Sirona Biochem Corp. (SBM) opened trading at C$0.31.

More From The Market Herald
Knight Therapeutics - President and CEO, Samira Sakhia.

" Knight Therapeutics (TSX:GUD) relaunches AKYNZEO in Brazil

Knight Therapeutics’ (GUD) affiliate United Medical has relaunched AKYNZEO in Brazil.

" Satellos Bioscience (TSXV:MSCL) changing the way we think of degenerative muscle diseases

Satellos Bioscience (MSCL) has filed a patent application with the US Patent and Trademark Office.

" NervGen Pharma (TSXV:NGEN) announces US$15M private placement

NervGen Pharma (NGEN) has announced a non-brokered private placement for gross proceeds of US$15,225,000.

" Feeding our plant-based future

One of the fastest-growing segments today is the plant-based industry, as the push towards cleaner lifestyles, eating habits, and sustainable living choices fuel